NCT00004066View on ClinicalTrials.gov

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
Ovarian CancerSarcomaSmall Intestine Cancer
Interventions
BIOLOGICAL

filgrastim

DRUG

docetaxel

DRUG

gemcitabine hydrochloride

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00004066 - Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter